A registration-quality trial of Firdapse for MuSK antibody positive Myasthenia Gravis.

Trial Profile

A registration-quality trial of Firdapse for MuSK antibody positive Myasthenia Gravis.

Planning
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Myasthenia gravis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2016 New trial record
    • 09 Aug 2016 According to Catalyst Pharmaceuticals media release, based on the positive data from another study (see profile 267531) company plans to initiate this trial. Special Protocol Assessment request has been submitted to the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top